Galetin A - Search Results

1

Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.

Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, Galetin A. Guest EJ, et al. Among authors: galetin a. Br J Clin Pharmacol. 2011 Jan;71(1):72-87. doi: 10.1111/j.1365-2125.2010.03799.x. Br J Clin Pharmacol. 2011. PMID: 21143503 Free PMC article.

2

Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach.

Galetin A, Clarke SE, Houston JB. Galetin A, et al. Drug Metab Dispos. 2002 Dec;30(12):1512-22. doi: 10.1124/dmd.30.12.1512. Drug Metab Dispos. 2002. PMID: 12433827

3

Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.

Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Stone AN, et al. Among authors: galetin a. Drug Metab Dispos. 2003 Sep;31(9):1086-9. doi: 10.1124/dmd.31.9.1086. Drug Metab Dispos. 2003. PMID: 12920162

4

Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.

Galetin A, Clarke SE, Houston JB. Galetin A, et al. Drug Metab Dispos. 2003 Sep;31(9):1108-16. doi: 10.1124/dmd.31.9.1108. Drug Metab Dispos. 2003. PMID: 12920166

5

Progress towards prediction of human pharmacokinetic parameters from in vitro technologies.

Houston JB, Galetin A. Houston JB, et al. Among authors: galetin a. Drug Metab Rev. 2003 Nov;35(4):393-415. doi: 10.1081/dmr-120026870. Drug Metab Rev. 2003. PMID: 14705868 Review.

6

Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.

Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. Uchaipichat V, et al. Among authors: galetin a. Drug Metab Dispos. 2004 Apr;32(4):413-23. doi: 10.1124/dmd.32.4.413. Drug Metab Dispos. 2004. PMID: 15039294

7

Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.

Galetin A, Brown C, Hallifax D, Ito K, Houston JB. Galetin A, et al. Drug Metab Dispos. 2004 Dec;32(12):1411-20. doi: 10.1124/dmd.104.000844. Epub 2004 Sep 1. Drug Metab Dispos. 2004. PMID: 15342470

8

Modelling atypical CYP3A4 kinetics: principles and pragmatism.

Houston JB, Galetin A. Houston JB, et al. Among authors: galetin a. Arch Biochem Biophys. 2005 Jan 15;433(2):351-60. doi: 10.1016/j.abb.2004.09.010. Arch Biochem Biophys. 2005. PMID: 15581591 Review.

9

CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.

Galetin A, Ito K, Hallifax D, Houston JB. Galetin A, et al. J Pharmacol Exp Ther. 2005 Jul;314(1):180-90. doi: 10.1124/jpet.104.082826. Epub 2005 Mar 22. J Pharmacol Exp Ther. 2005. PMID: 15784650 Free article.

10

Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans.

Rawden HC, Carlile DJ, Tindall A, Hallifax D, Galetin A, Ito K, Houston JB. Rawden HC, et al. Among authors: galetin a. Xenobiotica. 2005 Jun;35(6):603-25. doi: 10.1080/00498250500162870. Xenobiotica. 2005. PMID: 16192111

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

131 results

Search Page

Filters